Reuters logo
Roche Q3 sales beat forecasts as Ocrevus shines
October 19, 2017 / 5:22 AM / a month ago

Roche Q3 sales beat forecasts as Ocrevus shines

ZURICH, Oct 19 (Reuters) - Roche’s third-quarter sales rose 6 percent, beating analyst forecasts as the company was helped by better-than-expected revenue from its new multiple sclerosis medicine Ocrevus, the Swiss drugmaker said on Thursday.

Roche third-quarter sales were 13.1 billion Swiss francs($13.37 billion), compared to the 13.04 billion francs average estimate by analysts in a Reuters poll. Sales of Ocrevus were 308 million francs, better than the poll average of 228 million and accelerating from 192 million francs in the second quarter. ($1 = 0.9801 Swiss francs) (Reporting by John Miller; Editing by Michael Shields)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below